MiNK Therapeutics will release Q2 2025 financial results on August 14, 2025, followed by a conference call.
Quiver AI Summary
MiNK Therapeutics, Inc. announced that it will release its second quarter 2025 financial results on August 14, 2025, before the market opens. The company, which focuses on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and other immune-related diseases, will hold a conference call and webcast at 8:30 a.m. ET that day to discuss the results and provide corporate updates. Investors can access the conference call via specific dial-in numbers and will also find a live webcast available on the company's website. MiNK Therapeutics, headquartered in New York, is advancing a pipeline of therapies designed for scalable and off-the-shelf delivery. The press release also contains cautionary statements regarding forward-looking information that may carry risks and uncertainties.
Potential Positives
- Announcement of second quarter 2025 financial results scheduled for August 14, 2025, demonstrates transparency and commitment to keeping stakeholders informed.
- Conference call and webcast to discuss results and corporate updates provide an opportunity for direct engagement with investors and analysts.
- Highlighting the company's pioneering efforts in allogeneic iNKT cell therapies reinforces its innovative position within the biopharmaceutical industry.
- Details about scalable and reproducible manufacturing processes for off-the-shelf therapies may attract interest from investors looking for sustainable business models.
Potential Negatives
- The announcement of the upcoming financial results does not provide any positive updates or achievements, which may signal a lack of progress.
- The heavy emphasis on forward-looking statements and caution regarding their reliability may indicate underlying uncertainties about the company's future performance.
- The mention of risks and uncertainties in the company's future performance could raise concerns among investors about the stability and viability of its business model.
FAQ
When will MiNK Therapeutics release its Q2 2025 financial results?
MiNK Therapeutics will release its second quarter 2025 financial results on August 14, 2025, before the market opens.
How can I access the MiNK Therapeutics conference call?
The conference call can be accessed by dialing 646-307-1963 (New York) or 800-715-9871 (USA & Canada) at 8:30 a.m. ET on August 14.
Where can I find the webcast of the conference call?
A live webcast and replay will be available on the Events & Presentations page of MiNK's website.
What is MiNK Therapeutics focused on developing?
MiNK Therapeutics focuses on developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases.
How can investors stay updated on MiNK Therapeutics?
Investors can find important information on MiNK Therapeutics' website and social media channels.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$INKT Hedge Fund Activity
We have seen 0 institutional investors add shares of $INKT stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC removed 23,418 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $202,331
- RENAISSANCE TECHNOLOGIES LLC removed 10,171 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $87,877
- GEODE CAPITAL MANAGEMENT, LLC removed 9,611 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $83,039
- BLACKROCK, INC. removed 8,828 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $76,273
- STATE STREET CORP removed 2,552 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $22,049
- WELLS FARGO & COMPANY/MN removed 1,008 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $8,709
- TOWER RESEARCH CAPITAL LLC (TRC) removed 540 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $4,665
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its second quarter 2025 financial results before the market opens on Thursday, August 14, 2025. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.
Conference Call
Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada)
Conference ID: 1149380
Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at:
https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/qjwyn82w
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
917-362-1370
Media Contact
Source: MiNK Therapeutics
